The Bcl-2 proteins are less expressed in triple-negative breast cancer cells compared to other BC cells, therefore, being less sensitive to ABT–199 (a BH3 mimetic drug)-induced cell death. This evidence concerns the gene BCL2 and triple-negative breast carcinoma.